AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of this phosphatase, in turn, induces the PI3K/AKT pathway, leading to improved cell survival and resistance to apoptosis, thus emphasizing the role played by this phosphatase in CML [159].